Now is our last chance to get our voice heard in consultations prior to the 2018 Federal budget. Support the full implementation of the Naylor report. Visit SupportTheReport.ca to see ways to get involved.
Multiple Sclerosis is known as a progressive disease in which symptoms worsen over time. But for some 85% of those who suffer, the first stages of the illness come in waves. The individual may feel perfectly well some days while others are marked with worsening or new symptoms.
Officially this condition is known as relapsing remitting multiple sclerosis (MS) and it is the focus of a large Canadian conglomerate known as the CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis, or ECoMS. As the name implies, the group aims to determine how co-existing chronic diseases – comorbidities – affect those suffering with MS. Last week, representatives of the team, headed by Dr. Ruth Ann Marrie at the University of Manitoba and Director of Manitoba’s MS Clinic at Health Sciences Centre Winnipeg, revealed their findings in the journal, Neurology.
Nerve injuries and neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Multiple Sclerosis (MS) and glaucoma share some characteristics, one of which is the degeneration of a part of neurons called the axon. Axons are long extensions that branch out of the cell body to allow neurons to connect to other cells, including other neurons, to transmit signals. A team led by SickKids scientist David Kaplan with Freda Miller and their trainees Konstantin Feinberg and Adelaida Kolaj has recently identified a drug, called fortetinib, that protects axons from degeneration in multiple conditions. It may turn out to be a clinically useful therapeutic drug.
Injury of the spinal cord is a traumatic and life-changing event that affects over three million people worldwide. Over the last decade, researchers have been examining ways to help repair injured individuals through the use of stem cell transplantation. Significant progress has been made in this area yet many unanswered questions remain. For the laboratory of Dr. Wolfram Tetzlaff at the University of British Columbia, these gaps need to be filled to ensure successful treatments in the future.
Concussion affects the developing adolescent brain and may delay key cognitive processes, hampering the brain’s ability to change focus and pay attention. New research from Dr. Naznin Virji-Babul’s team, published today in the journal ASN Neuro, shows that concussion changes the way that different neural networks interact, stalling the brain in a state of cognitive inflexibility.
Even at rest, the brain is continuously active, processing and exchanging information. This active interaction between different parts of the brain is necessary for a person to be aware of her surroundings, or to be able to focus on his work or switch between tasks. In the concussed brain, this spontaneous exchange between brain regions is hampered, causing difficulties with concentration or shifting attention. In the adolescent brain, this has long-term implications for growth and development, especially in the prefrontal cortex where functions like learning, perception, and memory are processed. In the short term, this can mean an inability to focus on academic tasks and homework, or to tune out distractions or focus on urgent stimuli such as while driving.
For the past three years, Dr. Terrance Snutch and research associate Dr. John Tyson have been working with Oxford Nanopore Technologies (ONT) to develop a novel deoxyribonucleic acid (DNA) sequencing tool with promising implications for personalized medicine. About the size of a mobile phone, the MinION device is a USB-powered DNA sequencer capable of mapping complex genomic structures; with it, researchers were recently able to assemble a complete human genome using reads hundreds of times larger than has previously been possible with conventional methods.
Research from the IRCM contributes to our understanding of how our brain locates painful stimuli
When you experience a painful sensation such as touching a hot stove with your hand, the pain is restricted to your hand, allowing you to remove it quickly from the source of heat. How does the brain know that the pain is indeed coming from your hand and not from anywhere else on your body? Work recently published by Montreal Clinical Research Institute (IRCM) researchers help clarifying this question.
University of Calgary research study benefits people with severe essential tremor
Elias Pharaon is 85 years old and can sign his name for the first time in five years thanks to a new way to do brain surgery. Performed by a team of University of Calgary physicians and researchers with the Hotchkiss Brain Institute, magnetic resonance guided focused ultrasound (MRgFUS) is a new technology that allows surgeons to access the brain without cutting the skin or drilling into the skull.
Pimozide, known for treating certain psychiatric conditions, may stabilize progression of the disease. The University of Calgary’s Lawrence Korngut is leading a clinical trial with nine hospital centres across Canada to recruit patients for further study.
If you took part in the ALS Ice Bucket Challenge, you may have wondered where the money raised by the millions of people who poured buckets of ice water over their heads went. Some of those funds are being invested in a University of Calgary research study investigating a potential drug treatment for amyotrophic lateral sclerosis (ALS) patients.
UCalgary researchers discover stress isn’t just contagious; it alters the brain on a cellular level
In a new study in Nature Neuroscience, Jaideep Bains, PhD, and his team at the Cumming School of Medicine’s Hotchkiss Brain Institute (HBI), at the University of Calgary have discovered that stress transmitted from others can change the brain in the same way as a real stress does. The study, in mice, also shows that the effects of stress on the brain are reversed in female mice following a social interaction. This was not true for male mice.